Jan Bewersdorf, MD, discusses the design of an ongoing phase 1 trial investigating ruxolitinib plus abemaciclib in patients with primary or secondary myelofibrosis.
Jan Philipp Bewersdorf, MD
Advertisement
Articles by Jan Philipp Bewersdorf, MD
Jan Philipp Bewersdorf, MD, discusses the role of allogeneic hematopoietic cell transplant in myelofibrosis.
Advertisement
Latest Updated Articles
Dr Bewersdorf on Ruxolitinib Plus Abemaciclib in MyelofibrosisPublished: July 28th 2023 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
3
Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM
4
Ixazomib-Based Regimens Expand Options in Relapsed/Refractory Multiple Myeloma
5